OncoSec Medical Incorporated Share Price

Equities

ONCSQ

US68234L4059

Biotechnology & Medical Research

Market Closed - OTC Markets 17:40:01 23/04/2024 BST 5-day change 1st Jan Change
0.0002 USD 0.00% Intraday chart for OncoSec Medical Incorporated 0.00% 0.00%
Sales 2021 - Sales 2022 - Capitalization 28.35M 2.26B
Net income 2021 -45M -3.59B Net income 2022 -34M -2.71B EV / Sales 2021 -
Net cash position 2021 33.63M 2.68B Net cash position 2022 1.12M 89.73M EV / Sales 2022 -
P/E ratio 2021
-1.59 x
P/E ratio 2022
-0.83 x
Employees 41
Yield 2021 *
-
Yield 2022
-
Free-Float 84.57%
More Fundamentals * Assessed data
Dynamic Chart
Current month+100.00%
1 month+100.00%
3 months+100.00%
6 months-99.31%
More quotes
1 month
0.00
Extreme 0
0.00
Current year
0.00
Extreme 0
0.00
1 year
0.00
Extreme 0
1.31
3 years
0.00
Extreme 0
111.76
5 years
0.00
Extreme 0
179.52
10 years
0.00
Extreme 0
3 960.00
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 31/12/13
Corporate Officer/Principal - 11/10/20
Corporate Officer/Principal - 17/02/21
More insiders
Date Price Change Volume
26/04/24 - +-NaN% 1
25/04/24 - -100.00% 37
23/04/24 0.0002 +∞% 3,944
19/04/24 - -100.00% 1

Delayed Quote OTC Markets, April 23, 2024 at 05:40 pm

More quotes
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec Medical System EP device (the OMS EP Device) and a DNA plasmid delivery and application method that enables transient expression of recombinant therapeutic molecules in cells. The OMS EP Device is designed to promote cellular uptake of plasmid DNA injected directly into solid tumors to allow subsequent expression of the encoded therapeutic protein. The OMS EP Device can be adapted to treat different tumor types and consists of an electrical pulse generator and a disposable applicator. Its lead product candidate, tavokinogene telseplasmid (TAVO), is a plasmid encoding human interleukin-12.
More about the company